The Peptide Field. Insulin: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/insulin

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=insulin#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Several FDA-approved insulin products exist, including highly similar versions called biosimilars

Exact product limits: The name insulin covers many FDA-approved products. They can differ in the amount of medicine, how long they work, how they enter the body, and what their labels allow.

Human outcomes: Strong. Long-term studies that assigned people to groups by chance support closely monitored insulin treatment for specific groups with diabetes.

Body effects in people: Strong. Studies describe when each product starts working, reaches its strongest effect, and wears off.

What the evidence shows: The Diabetes Control and Complications Trial (DCCT) put 1,441 people with type 1 diabetes into groups by chance. It compared an intensive insulin plan with a less intensive plan. It followed them for about 6.5 years. The intensive plan lowered the risk of new or worsening eye, kidney, and nerve problems. It also led to two to three times as many severe low-blood-sugar events. Insulin is essential for type 1 diabetes. Insulin treats other forms of diabetes too.

What remains unknown: One insulin plan is not right for everyone. Products, schedules, targets, and treatment levels vary by person and product. Evidence for one product, group, or plan does not support switching products on your own. It also does not show that every product can be exchanged freely or used for non-medical reasons.

Safety limits: Hypoglycemia means dangerously low blood sugar. It can be severe and life-threatening. Product mix-ups and changes without medical guidance can cause serious harm. This guide does not give dose calculations, correction factors, injection steps, or advice for changing an insulin plan.

Product record: Humalog. Form: Several strengths and delivery forms listed in the label. Route: Injection under the skin. Humalog U-100 can also be used in some insulin pumps. Its label allows medical staff to give the U-100 form through a vein after dilution and with close monitoring. The U-200 form must not be used through a vein..
Scope: Diabetes treatment for the people and uses listed in the current Humalog label. This example does not describe every insulin product.
Published label: May 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020563s214%2C205747s038lbl.pdf

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. Insulin: patient and product overview. 2026. Accessed 2026-08-30. https://www.fda.gov/consumers/free-publications-women/insulin

DailyMed · National Library of Medicine. HUMALOG (insulin lispro) label, updated June 2026. 2026. Accessed 2026-08-30. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f

U.S. Food and Drug Administration. HUMALOG (insulin lispro) FDA prescribing information, revised 05/2025. 2025. Accessed 2026-08-30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020563s214%2C205747s038lbl.pdf

PubMed · New England Journal of Medicine. The effect of intensive treatment of diabetes on long-term complications in insulin-dependent diabetes mellitus. 1993. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/8366922/

PubMed · Diabetes. Hypoglycemia in the Diabetes Control and Complications Trial. 1997. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/9000705/

U.S. Food and Drug Administration. FDA approves the first rapid-acting insulin biosimilar product for diabetes. 2026. Accessed 2026-08-30. https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes

U.S. Food and Drug Administration. Biosimilars basics for patients. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/biosimilars/biosimilars-basics-patients

World Anti-Doping Agency. 2026 WADA Prohibited List. 2026. Accessed 2026-08-30. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Keep the limits, review date, and sources with this record. Check the current source for changes.